Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Capricor Therapeutics: Vorbörslicher Kurssprung vor richtungsweisender FDA-Entscheidung (Investing.com DE) +++ CAPRICOR THERAPEUTICS Aktie -6,78%

SAVARA Aktie

 >SAVARA Aktienkurs 
4.063 EUR    -14.3%    (TradegateBSX)
Ask: 4.064 EUR / 1000 Stück
Bid: 3.855 EUR / 1000 Stück
Tagesumsatz: 16389 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
SAVARA Aktie über LYNX handeln
>SAVARA Performance
1 Woche: +7,7%
1 Monat: +18,6%
3 Monate: -0,1%
6 Monate: +13,8%
1 Jahr: +19,9%
laufendes Jahr: -11,4%
>SAVARA Aktie
Name:  SAVARA INC. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US8051111016 / A2DQ2B
Symbol/ Ticker:  YB4P (Frankfurt) / SVRA (NASDAQ)
Kürzel:  FRA:YB4P, ETR:YB4P, YB4P:GR, NASDAQ:SVRA
Index:  -
Profil:  Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company’s work centers on developing inhaled therapies designed to address serious lung disorders with limited treatment options, with a particular ..
>Volltext..
Marktkapitalisierung:  1048.5 Mio. EUR
Unternehmenswert:  960.84 Mio. EUR
Umsatz:  -
EBITDA:  -142.87 Mio. EUR
Nettogewinn:  -139.32 Mio. EUR
Gewinn je Aktie:  -0.56 EUR
Schulden:  27.7 Mio. EUR
Liquide Mittel:  27.19 Mio. EUR
Operativer Cashflow:  -118.87 Mio. EUR
Bargeldquote:  7.8
Umsatzwachstum:  -
Gewinnwachstum:  -36.81%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  SAVARA
Letzte Datenerhebung:  20.11.26
>SAVARA Kennzahlen
Aktien/ Unternehmen:
Aktien: 220.62 Mio. St.
Frei handelbar: 50.12%
Rückkaufquote: -11.76%
Mitarbeiter: 70
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 110.18%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 10.09
PEG-Ratio: -0.53
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -102.9%
Eigenkaprendite: -151.05%
>SAVARA Peer Group
Gesundheit, Lungen- & Atemwegserkrankungen/ -behandlung, Autoimmunerkrankungen
 
20.11.26 - 14:54
Savara-Aktie bricht vorbörslich ein: FDA verschiebt Zulassungsentscheidung auf unbestimmte Zeit (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
20.11.26 - 14:48
Savara shares fall 20% as FDA says it will miss Molgramostim review deadline (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
12.11.26 - 22:09
Savara Announces New Employment Inducement Grant (Business Wire)
 
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On November 10, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to seven new employees who recently joined the Company. The inducement awards consist of options to purchase 20,500 shares of the Company's common stock, restricted stock units (RSUs) covering 38,500 shares of the Company's common stock, and performance stock units (PSUs) covering 8,000 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees' acceptance of employment with the Company. The options have an exercise price of $4.92 per share, the closing trading price of the Company's common stock on the NASDAQ Global Marke...
20.08.26 - 22:06
Savara Announces New Employment Inducement Grant (Business Wire)
 
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company's common stock and restricted stock units (RSUs) covering 64,500 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees' acceptance of employment with the Company. The options have an exercise price of $5.37 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date. Each option has a 10-year term and vests as to 1/16th of the number...
11.08.26 - 22:09
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire)
 
MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026 MOLBREEVI MAAs Under Review by the EMA and the U.K.'s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectively Data Presented at ATS Showed Molgramostim Demonstrated Continuous Long-term Improvements in Lung Function and Respiratory Health-Related Quality of Life European and Australian Patent Offices Granted MOLBREEVI Liquid Formulation Patents, Providing Protection until March 2041 ~$173M in Cash and Short-Term Investments as of June 30, 2026, Plus up to ~$150M of Non-Dilutive Capital Upon FDA Approval of MOLBREEVI, Positions the Company Well for Launch LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update. “While we have regulatory applications under review across the U.S., EU, and U.K., the U.S. represents our nearest-term oppor...
22.07.26 - 16:45
Here′s Why You Should Add Savara Stock to Your Portfolio Now (Zacks)
 
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook....
27.06.26 - 17:48
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline (Fool)
 
This clinical-stage biotech focused on rare lung diseases reported significant insider selling amid a year of strong share gains....
23.06.26 - 05:01
Insiderhandel: Chief Financial Officer verkauft Aktien von Savara im Wert von 2241432 USD (Insiderkauf)
 
Lowrance, David L. - Vorstand - Tag der Transaktion: 2026-06-22...
12.06.26 - 22:12
Savara Announces New Employment Inducement Grant (Business Wire)
 
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase 36,500 shares of the Company's common stock, restricted stock units (RSUs) covering 42,500 shares of the Company's common stock, and performance stock units (PSUs) covering 8,000 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees' acceptance of employment with the Company. The options have an exercise price of $5.27 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market o...
08.06.26 - 22:30
Savara CFO to step down (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.06.26 - 22:06
Savara Announces Chief Financial and Administrative Officer Transition (Business Wire)
 
-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer -- -- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, M.B.A., the Company's Chief Operating Officer, will assume the additional role of Chief Financial Officer, while the administrative responsibilities will be distributed among members of the senior leadership team. “We are grateful to Dave as his leadership has been a vital part of Savara's growth for nearly ten years,” said Matt Pauls, J.D., M.B.A., Chair and Chief Executive Officer, Savara. ??...
17.04.26 - 22:06
Savara Announces New Employment Inducement Grant (Business Wire)
 
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On April 14, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to 24 new employees who recently joined the Company. The inducement awards consist of options to purchase 18,500 shares of the Company's common stock, restricted stock units (RSUs) covering 141,000 shares of the Company's common stock, and performance stock units (PSUs) covering 85,000 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees' acceptance of employment with the Company. The options have an exercise price of $6.07 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market ...
16.04.26 - 12:54
Savara gets FDA review extension for lead asset (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.04.26 - 18:00
(3⁺) Chart Tracker: Tesla, SAP, Adobe, Savara (Stock3)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
15.03.26 - 16:12
VR Adviser Adds Over 1 Million Savara Shares (Fool)
 
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials....
13.03.26 - 20:33
Savara GAAP EPS of -$0.13 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.03.26 - 13:06
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update (Business Wire)
 
Achieved Regulatory Milestones for the MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Development Program: U.S. Food and Drug Administration (FDA) filed the Biologics License Application (BLA) Priority Review granted, Prescription Drug User Fee Act (PDUFA) date set for August 22, 2026 FDA indicated an Advisory Committee is not planned for the BLA Submitted Marketing Authorization Applications (MAAs) to the European Medicines Agency (EMA) and the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) With ~$236M in Cash and Short-Term Investments as of December 31, 2025, and Access to up to an Additional ~$150M of Non-Dilutive Capital upon FDA Approval of MOLBREEVI, the Company is Well Capitalized for Launch LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business...
20.02.26 - 22:48
FDA to review Savara resubmitted Molbreevi BLA (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.02.26 - 22:09
Savara Announces New Employment Inducement Grant (Business Wire)
 
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On February 10, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 7,500 shares of the Company's common stock and restricted stock units (RSUs) covering 7,500 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees' acceptance of employment with the Company. The options have an exercise price of $5.27 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date. Each option has a 10-year term and vests as to 1/16th of the number o...
27.01.26 - 14:06
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* (Business Wire)
 
-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI --LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity. Under the terms of the amended loan agreement, up to an additional $75 million will become available upon FDA's approval of MOLBREEVI, the Company's investigational therapy in autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The loan agreement maturity date and interest-only period remain unchanged. There are no warrants in connection with the agreement. “In anticipation of the potential approval of MOLBREEVI later this year, Savara will be well capitalized with ~$150 million of non-dilutive capital to support launch activities,” said...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Unrat ist nicht das Gegenteil von Rat. - Dr. Fritz P. Rinnhofer
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!